⌘K
Loading ticker…
As of 2026-08-24, Elanco Animal Health Incorporated Common Stock (ELAN) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.2%, relative volume 0.46×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ELAN is in a stage 1 base, week 1. Currently in a 124-day base; basing ADR 4.1% (broad 3.0%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: -0.5% / 3.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ELAN is held by 41 ETFs as of May 2026. Top owner: VHT at 0.19% weight, $36M notional. Top 3 carry $87M.
Held by 142 ETFs · $2.3B across latest filings · largest weight 3.59% (ADPV).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.19% | $36M | — |
| SCHMSchwab U.S. Mid-Cap ETF | 0.22% | $32M | −0.04 pp |
| IVOO | 0.34% | $19M | −0.04 pp |
| CGMM | 0.47% | $13M | new |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $13M |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| — |
| IVOG | 0.65% | $12M | −0.08 pp |
| VONVVanguard Russell 1000 Value ETF | 0.03% | $7M | — |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.03% | $7M | −0.01 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $7M | — |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.04% | $6M | — |
Showing 10 of 41 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ELAN Jan avg: 4.26% median: 2.87% win: 50% σ: 6.40% n: 4 2022-04-12 → 2026-07-31 | ELAN Feb avg: -1.54% median: 0.33% win: 50% σ: 12.47% n: 4 2022-04-12 → 2026-07-31 | ELAN Mar avg: -7.74% median: -7.68% win: 25% σ: 8.48% n: 4 2022-04-12 → 2026-07-31 | ELAN Apr avg: -7.46% median: -6.52% win: 20% σ: 7.64% n: 5 2022-04-12 → 2026-07-31 | ELAN May avg: 12.49% median: 6.62% win: 60% σ: 24.62% n: 5 2022-04-12 → 2026-07-31 | ELAN Jun avg: -0.54% median: 3.19% win: 60% σ: 17.53% n: 5 2022-04-12 → 2026-07-31 | ELAN Jul avg: 3.30% median: 3.21% win: 60% σ: 11.36% n: 5 2022-04-12 → 2026-07-31 | ELAN Aug avg: 7.13% median: 9.86% win: 75% σ: 25.50% n: 4 2022-04-12 → 2026-07-31 (current) | ELAN Sep avg: -5.28% median: -6.46% win: 25% σ: 11.46% n: 4 2022-04-12 → 2026-07-31 | ELAN Oct avg: -4.83% median: -3.84% win: 50% σ: 15.36% n: 4 2022-04-12 → 2026-07-31 | ELAN Nov avg: 10.21% median: 4.78% win: 75% σ: 16.03% n: 4 2022-04-12 → 2026-07-31 | ELAN Dec avg: 2.59% median: -3.90% win: 25% σ: 16.09% n: 4 2022-04-12 → 2026-07-31 |